The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
2.
M13 BACTERIOPHAGE WITH A HIGH CYSTEINE CONTENT AND GENETICALLY ENGINEERABLE HYDROGELS
The present invention discloses antibodies capable of binding to and neutralizing SARS-CoV-2 and variants thereof. The invention also discloses a cell-free antibody engineering platform capable of identifying antibodies that bind to specific target molecules and virus-neutralizing antibodies.
Described are devices and methods for measuring semiconductor materials, devices, circuits, and systems. The device includes a probe head that accepts multiple optical assemblies. At least one optical assembly provides a light source, and at least one optical assembly provides a detector. Both are coupled to the probe head. The optical assemblies may be manually or automatically adjustable using kinematic mounts, and may include optical fibers for conveying light to and from a sample. Each optical assembly may include a lens stack or an objective. Illumination and collection assemblies may share a common focal point, and different subsets of assemblies may share different focal points. The device may include a sample bed for imaging multiple samples at once, and may be coupled to a control system for automatically positioning the samples and/or the optical assemblies.
Provided herein are compounds that inhibit the function of MYB. In particular, provided are compounds that can inhibit MYB and/or disrupt the interaction between MYB and a protein associated with MYB, a protein whose dysregulation is implicated in cancer. Also provided are pharmaceutical compositions comprising the compounds, methods of inhibiting MYB function, and methods of treating cancer in a subject by administering a compound or composition described herein.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present description provides methods, assays and reagents useful for sequencing proteins. Sequencing proteins in a broad sense involves observing the plausible identity and order of amino acids, which is useful for sequencing single polypeptide molecules or multiple molecules of a single polypeptide. In one aspect, the methods are useful for sequencing multiple polypeptides. The methods and reagents described herein can be useful for high resolution interrogation of the proteome and enabling ultrasensitive diagnostics critical for early detection of diseases.
This disclosure relates to new multi-modal sensing array architectures that can sense normal and shear forces. Examples include resistive sensing arrays that are used to measure changes in the environment and manufacturing processes to produce multi-modal sensing arrays in a highly-automated and inexpensive fashion. Specifically, a manufacturing process includes a cutting operation and sewing/embroidery technique that creates a fully automated process to produce a resistive sensing array. The new manufacturing process enables the reduction of processing time and materials to produce a functioning sensor without limiting the designs space of achievable sensor geometries. Also presented are sensor reading methodologies for high-speed reading that are capable of sensing vibrations and a wide range of forces. Examples include the use of the new sensor arrays in wearable devices.
G06F 3/045 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means using resistive elements, e.g. a single continuous surface or two parallel surfaces put in contact
G01L 1/20 - Measuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress
G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
8.
NANO-PHASE SEPARATING NI POWDER AND THE METHODOLOGY TO IDENTIFY THEM
A method of forming nonplanar nanostructures on a substrate is disclosed. The method includes treating a portion of the surface of the substrate so as to affect its properties. A film is then applied to the substrate after the surface engineering has been completed. Energy is then applied to the film, causing it to delaminate in the regions where the surface was treated, thereby creating the nonplanar nanostructures. The surface treatment may include the application of a self-assembled molecular (SAM) layer, which includes an anchoring group that allows assembly on the surface of the substrate, and also has a functional group that has the desired interaction with the film. The nonplanar nanostructures may be used to form nanoswitches, resonators, and strain engineered surfaces.
B32B 3/08 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by features of form at particular places, e.g. in edge regions characterised by added members at particular parts
B32B 3/10 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material
B32B 3/18 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by an internal layer formed of separate pieces of material
B32B 1/06 - Layered products essentially having a general shape other than plane characterised by fillings or added members in hollow portions
10.
GUESSING RANDOM ADDITIVE NOISE DECODING (GRAND) WITH QUANTISED SOFT DECISION INFORMATION
We disclose a soft-detection variant of Guessing Random Additive Noise Decoding (GRAND) called discretized soft-information for GRAND (DSGRAND) that can efficiently decode any moderate redundancy block-code in an algorithm that is suitable for highly parallelized implementation in hardware. DSGRAND provides near maximum likelihood decoding performance when provided with five or more bits of soft information per received bit, by discretizing the soft information into noise effect sequences and allocating those sequences into bins according to weight. The use of these bins provides a separate, simplified manner of sequencing noise guessing.
The disclosure provides, in various embodiments, methods of treating fungal infections in subjects in need thereof, methods of attenuating virulence of fungi (e.g., in subjects in need thereof), and methods of inhibiting formation of fungal biofilms on surfaces (e.g., living or inert surfaces) with mucin glycans, tautomer, stereoisomer and/or pharmaceutically acceptable salts thereof. The disclosure further provides, in various embodiments, mucin glycan compositions, such as synthetic mucin glycans and defined mucin glycan compositions.
e.g.e.g., e.g., mRNA vaccines). In still further embodiments, the disclosure provides methods and compositions for enhancing one or more vaccines, such as SARS- CoV-2 mRNA vaccines.
The acoustic fiber transducer has a piezoelectric domain with Young's modulus, Epiezo, and including a non-centrosymmetric crystalline-phase piezoelectric material and inorganic piezoelectric particles. At least one charge collector domain is in electrical connection with the piezoelectric domain and includes an electrically conductive material operative to collect electrical charge generated in the piezoelectric domain. At least one electrical conductor is in electrical contact with the at least one charge collector domain and includes an electrically conductive material operative to transport electrical charge from a charge collector domain to an end of the acoustic fiber transducer as an electrical signal indicative of input acoustic sound pressure on a matrix of textile fibers that includes the acoustic fiber transducer. Outer acoustic energy transmission material has a Young's modulus Etrans, of 0.3 Pa-500 MPa, for matching vibrational modes of the textile fiber matrix. A ratio of Epiezo/Etrans is between about 5 and about 70,000.
Methods for designing scaffolded RNA nanostructures of desired shape are described. In some forms, the methods design nucleic acid “staple” sequences that hybridize to a user-defined RNA scaffold and fold it into the desired shape based on A-form helical nucleic acid geometry. In some forms, the methods implement asymmetry in nucleotide positions across two helices of an edge to account for A-form nucleic acid geometry. In preferred forms, crossover asymmetry is implemented in the staples. In other forms, crossover asymmetry is implemented in the RNA scaffold. In other forms, the methods do not introduce crossover asymmetry. Scaffolded RNA nanostructures produced according to the methods including messenger RNAs, replicating RNAs, functional RNAs and other RNA species within the scaffold, staples, or both scaffold and staples are provided. Modified nanostructures including chemically modified nucleotides are also described.
The present disclosure relates to proteins comprising a target-binding domain for detection of a target of interest, methods, compositions and kits thereof.
G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent
C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
C07K 14/33 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
16.
Synell Creation, Evolution, And Digital Transmission
Synells are created by encapsulating components and iteratively optimizing each synell for a desired trait. Each synell is tested during each interation. Failed synells are discarded. Additional synell components are added during each iteration, with iterative optimization being repeated until synells having the trait are created. A method for synell reproduction includes creating a synell having a desired trait, determining a recipe for the synell, digitizing the recipe, and transmitting the digitized recipe to another location. The recipe is reconstituted at the other location and the synell is reproduced using the recipe. On-demand biosynthesis of synells includes generating droplets containing different synell components within a microfluidic device, fusing them into combinations, and storing them until a request for a synell having a particular trait is received. Fused droplets having the component combination for the trait, or being combinable to produce it, are retrieved and encapsulated to form the requested synell.
Disclosed are nucleic acid-chromophores and nucleic acid assembly containing the nucleic acid-chromophores. The nucleic acid-chromophore contains a nucleic acid strand and two or more adjacent chromophores. The two or more adjacent chromophores can be covalently incorporated in the backbone of the nucleic acid strand. One or more photophysical properties of the adjacent chromophores can be altered by a change in the nucleic acid assembly. In some forms, the nucleic acid assembly can contain a nucleic acid scaffold. In these forms, the change in the nucleic acid assembly can be a change in the length of a nucleic acid hybrid in the nucleic acid scaffold that is opposite the adjacent chromophores. Typically, the nucleic acid hybrid does not contain any chromophore. The nucleic acid-chromophores can serve as molecular fluorophores with emission properties that are highly sensitive to local geometry and the chemical environment.
The gastrointestinal capsule provides mechanical stimulation within the gastrointestinal tract. The capsule may be deployed in a subject's gastrointestinal tract orally by the subject ingesting the capsule. The capsule may mechanically stimulate any desired region within the gastrointestinal tract, including the stomach, small intestine, and large intestine. The mechanical stimulations provided by the capsule are applied to a portion of the inner walls or lining of a section of the gastrointestinal tract to simulate satiety.
A61H 1/00 - Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
An ingestible capsule includes a housing forming a cavity and having a textured outer surface. The textured outer surface forms a helical depression and a plurality of protruding studs disposed in the helical depression. The capsule further includes a therapeutic agent disposed in or on the housing. The capsule also includes a biodegradable coating on the textured outer surface of the housing, the biodegradable coating configured to dissolve in a fluid having a pH of 1.5 to 9.
A61H 1/00 - Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
20.
ENDOVASCULAR INJECTABLE STENTS FOR CARDIOVASCULAR DRUG DELIVERY
Herein is described a stent platform capable of intravascular local delivery of therapeutics through multipoint injection of drug agents into the vascular walls and endocardial surfaces. More specifically, an endovascular injectable stent made of kirigami skin is wrapped around a soft linear actuator and used for intravascular local drug delivery of therapeutics. This platform addresses an unmet need of treating aortic stenosis and atherosclerotic cardiovascular disease.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
An injectable nanoparticular formulation and method of use thereof for treating non-compressible hemorrhage or internal bleeding has been developed. The formulation includes two interactive components, one a targeting nanoparticle with a polypeptide sequence that binds to a cell present at a site of injury, and the other a crosslinking nanoparticle with a bioorthogonal click-crosslinking group.
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRJSPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CR.ISPR-Cas enzyme systems. In particular the present invention comprehends engineered new guide architectures and enzymes to be used in optimized Staphylococcus aureus CRISPR-Cas enzyme systems.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G16B 15/30 - Drug targeting using structural data; Docking or binding prediction
Systems and methods for analyzing mechanical properties in-situ and in real-time of an object being additively manufactured are provided. Such systems can include an inducer (e.g., micro- or nano-inducer) that measures one or more parameters of the object being manufactured, such as a hardness or modulus of material deposited to form the object, and one or more cameras that generate one or more images of the object being manufactured. The measured parameter(s) and generated image(s) can be used by a controller in real-time to generate one or more topographic images of the object being printed and/or one or more 3D-maps of the object being printed. Alternatively, or additionally, the controller can be used to modify parameters that impact the object being printed, such as parameters associated with the printer or a surrounding print environment. Methods of printing based on such systems are also provided.
G01N 3/46 - Investigating hardness or rebound hardness by performing impressions under a steady load by indentors, e.g. sphere, pyramid the indentors performing a scratching movement
G05B 19/4099 - Surface or curve machining, making 3D objects, e.g. desktop manufacturing
B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
25.
PROGRAMMABLE INSERTION APPROACHES VIA REVERSE TRANSCRIPTASE RECRUITMENT
This disclosure provides complexes for prime editing comprising an RNA-guided nuclease, a fusion protein comprising a reverse transcriptase domain linked to a nucleic acid binding protein, and a guide RNA (gRNA) comprising at least one protein-recruiting stem-loop nucleic acid sequence, wherein the protein-recruiting stem-loop nucleic acid sequence binds to the nucleic acid binding protein. Also provided are systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE) with integration enzymes paired with the prime editing complex.
Several new techniques for designing nanophotonic scintillators which lead to optimal performance and novel functionalities. Important design concepts include the use of absorbing structures inspired by solar cells, angularly-selective structures, and metasurfaces. Scintillators based on conventionally overlooked materials (such as GaAs or GaN) are also disclosed, which are designed to reach efficiencies comparable or superior to state-of-the-art conventional scintillators (such as YAG:Ce and LYSO). Such scintillators provide important enhancement of scintillation yield arising from incorporation of nanophotonic patterns. Additionally, nanophotonic scintillators designed in conjunction with image post processing algorithms (such as deconvolution algorithms, tomographic reconstruction, etc.) are disclosed. These scintillators are designed in order to increase robustness, minimize the required dose/scan time or even the number of scans required in scintillation imaging. These new designs optimize the scintillator for optimal reconstruction.
Composite materials with few or no void defects are described. The composites can include nanoporous network materials. Methods and systems for the fabrication of the composite materials are generally described. According to certain embodiments, composite materials are fabricated without the use of an autoclave or low pressure environments.
B32B 5/06 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments characterised by a fibrous layer needled to another layer, e.g. of fibres, of paper
28.
SYSTEM AND METHOD FOR REAL-TIME DETERMINATION OF PARTICLE SIZE DISTRIBUTIONS IN DRY POWDERS
A method of monitoring a particle size distribution (PSD) is provided. A plurality of particles having a particle size distribution (PSD) may be illuminated by an at least partially coherent beam to produce scattered light. The scattered light may be captured by a pixelated photoelectric detector, thereby creating an ensemble of raw speckled images. Based on the ensemble of the raw speckled images, an ensemble-averaged intensity correlation may be computed. The ensemble-averaged intensity correlation may be provided to an inverse module. The inverse module may be configured to determine the PSD based on the ensemble-averaged intensity correlation. The particle size distribution may be obtained from the inverse module.
A method of monitoring a particle size distribution (PSD) is provided. At least a partially coherent pupil-engineered beam may be produced. A plurality of particles having a particle size distribution (PSD) may be illuminated by the pupil-engineered beam to produce scattered light. The scattered light may be captured by a pixelated photoelectric detector, thereby creating a raw speckled image. An intensity correlation of the raw speckled image may be computed. The intensity correlation may be provided to an inverse module. The inverse module may be configured to determine the PSD based on the intensity correlation. The PSD may be obtained from the inverse module.
6.250.2532126.250.253212 12 in water, and decomposing droplets by passing through a co-flow burner. Also disclosed is a method of produce producing a thin-tape comprising Al-LLZO.
Disclosed herein are methods for reducing bubble accumulation on electrodes. Related articles (e.g., electrodes or electrochemical cells) and systems are also described herein.
The disclosure provides various systems and methods for identifying individuals from one or more samples. In particular, improved systems and methods of analysis are provided for handling multiple contributors, as well as systems and methods that model not only individual error rates per locus but factor in amplification of errors induced through PCR cycles. In some embodiments, modeling of error rates can be applied in multi-contributor settings to more accurately establish real alleles from artifacts. Other aspects involve application of sequencing in error modeling. Further, methods are provided for determining the presence of common individual DNA profiles in one or more complex DNA mixtures and for deconvolution of multiple complex DNA mixtures into shared individual components. The methods of the disclosure do not require any prior knowledge of individual DNA profiles or contributors to the complex DNA mixtures. Moreover, the methods of the disclosure may use any SNP panel, including those panels already existing and those panels specifically designed to maximize performance characteristics of the methods described herein.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
33.
High-Speed Spatial Light Modulation and Quantum Control
An atom control architecture based on VIS-IR photonic integrated circuit (PIC) technology is characterized by (1) visible (VIS) and near-infrared (IR) wavelength operation, (2) channel counts extensible beyond 1000s of individually addressable atoms, (3) high intensity modulation extinction and (4) repeatability compatible with low gate errors, and (5) fast switching times. A 16-channel SiN-based APIC with (5.8±0.4) ns response times and <−30 dB extinction ratio at a wavelength of 780 nm. Based on a complementary metal-oxide-semiconductor (CMOS) fabrication process, this atom-control PIC (APIC) technology can be used for atomic, molecular, and optical physics and emerging applications, from quantum computers with cold atoms or ions to quantum networks with solid-state color centers. This APIC technology is especially suitable for scalable quantum information processing based on optically programmable atomic systems.
G02B 6/122 - Basic optical elements, e.g. light-guiding paths
G02B 6/124 - Geodesic lenses or integrated gratings
G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
The gastrointestinal capsule provides mechanical stimulation within the gastrointestinal tract. The capsule may be deployed in a subject's gastrointestinal tract orally by the subject ingesting the capsule. The capsule may mechanically stimulate any desired region within the gastrointestinal tract, including the stomach, small intestine, and large intestine. The mechanical stimulations provided by the capsule are applied to a portion of the inner walls or lining of a section of the gastrointestinal tract to simulate satiety.
A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a guide-RNA expression system for a eukaryotic host cell.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C07D 249/16 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 231/54 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
C07C 13/547 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings at least one ring not being six-membered, the other rings being at the most six-membered
37.
DEEP REINFORCEMENT LEARNING-ENABLED CRYO-EM DATA COLLECTION
Methods and systems for performing electron microscopy are provided. Microscopy images candidate sub-regions at different magnification levels are captured and provided to a trained sub-region quality assessment application trained to output a quality score for each candidate sub-region. From the quality scores, group-level features for the larger magnification images are determined using a group-level feature extraction application. The quality scores for the candidate sub-regions and the group-level extraction features are provided to a trained Q-learning network that identifies a next sub-region amongst the candidate sub-regions for capturing a micrograph image, where reinforcement learning may be used with the Q-learning network for such identification, for example using a decisional cost.
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
Methods of synthesis of nickel-rich cathode materials can include preheating droplets, decomposing the droplets in a burner, collecting solid particles, and calcinating the solid particles.
A method of synthesis of single crystal nickel-rich cathode materials can include preparing a precursor solution by dissolving lithium nitrate, nickel nitrate, manganese nitrate, and cobalt nitrate in water, aerosolizing the solution of a) in a stream of air using an ultrasonic sprayer, preheating the resulting droplets, premixing the droplets with methane, decomposing the droplets by passing through a co-flow burner, depositing solid particles on a filter, and calcinating the solid particles in a furnace in oxygen to produce a single crystal cathode material.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing online seminars and courses of instruction at the post-secondary and graduate levels; educational services, namely, providing online seminars and courses of instruction at the executive, professional, and continuing education levels; educational services, namely, conducting online education programs in the field of professional development; providing online reporting on the performance of learners in educational courses and seminars; online educational testing; providing information about online education
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing online seminars and courses of instruction at the post-secondary and graduate levels; educational services, namely, providing online seminars and courses of instruction at the executive, professional, and continuing education levels; educational services, namely, conducting online education programs in the field of professional development; providing online reporting on the performance of learners in educational courses and seminars; online educational testing; providing information about online education
42.
Radio-Frequency Photonic Architecture for Deep Neural Networks, Signal Processing, and Computing
A multiplicative analog frequency transform optical neural network (MAFT-ONN) encodes data in the frequency domain, achieves matrix-vector products in a single shot using photoelectric multiplication, and uses a single electro-optic modulator for the nonlinear activation of all neurons in each layer. Photoelectric multiplication between radio frequency (RF)-encoded optical frequency combs allows single-shot matrix-vector multiplication and nonlinear activation, leading to high throughput and ultra-low latency. This frequency-encoding scheme can be implemented with several neurons per hardware spatial mode and allows for an arbitrary number of layers to be cascaded in the analog domain. For example, a three-layer DNN can compute over four million fully analog operations and implement both a convolutional and fully connected layer. Additionally, a MAFT-ONN can perform analog DNN inference of temporal waveforms like voice or radio signals, achieving bandwidth-limited throughput, speed of light-limited latency, and fully analog complex-valued matrix operations.
A multi-sensor, real-time, in-process current and voltage estimation system is disclosed including sensors, affiliated hardware, and data processing algorithms that allow accurate estimation of currents and voltages from magnetic and electric field measurements, respectively. Aspects of the system may be embodied in a detector that is readily attachable to conductors of an energized system for contactless current and/or voltage sensing of the conductors without requiring the conductors to be disconnected from the energized system.
Methods of synthesis of nickel-rich cathode materials can include preheating droplets, decomposing the droplets in a burner, collecting solid particles, and calcinating the solid particles.
The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
46.
SMALL NOVEL CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF
Engineered or non-naturally occurring systems and compositions comprising novel Type V Cas polypeptides and orthologs thereof are disclosed herein. Also provided are methods of use for the novel Type V Cas polypeptide systems and compositions for reprogrammable targeting of nucleic acid and polynucleotide components.
47.
ADHESIVE BONDING FOR BIFACIAL AND TANDEM SOLAR CELLS
Disclosed herein are solar cells including a perovskite material and at least one adhesive layer, and methods of making the same. The methods provide solar cells in which transparent conductive oxide(s) have been annealed, and in which the perovskite material is not exposed to elevated temperatures which could degrade its performance.
A61Q 17/00 - Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A method includes inserting a high temperature superconductor (HTS) cable into a groove of a support structure; and flowing a molten metal into the HTS cable while the HTS cable is in the groove. A magnet structure includes a support structure having a groove; and a high temperature superconductor (HTS) cable comprising a metal at least partially filling the HTS cable, the HTS cable being disposed in the groove.
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Methods and systems for control of solid phase peptide synthesis are generally described. Control of solid phase peptide synthesis involves the use of feedback from one or more reactions and/or processes (e.g., reagent removal) taking place in the solid phase peptide synthesis system. In some embodiments, a detector may detect one or more fluids flowing across a detection zone of a solid phase peptide synthesis system and one or more signals may be generated corresponding to the fluid(s). For instance, an electromagnetic radiation detector positioned downstream of a reactor may detect a fluid exiting the reactor after a deprotection reactor and produce a signal(s). In some embodiments, based at least in part on information derived from the signal(s), a parameter of the system may be modulated prior to and/or during one or more subsequent reactions and/or processes taking place in the solid phase peptide synthesis system. In some embodiments, the methods and systems, described herein, can be used to conduct quality control to determine and correct problems (e.g., aggregation, truncation, deletion) in reactions (e.g., coupling reactions) taking place in the solid phase peptide synthesis system.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 33/487 - Physical analysis of biological material of liquid biological material
53.
SYSTEMS AND METHODS FOR ON-PERSON WEARABLE ELECTRONIC DEVICES
Systems and methods are provided for on-person wearable electronic devices configured for extended periods of wear. A couplant may be provided that is made of a soft anti-dehydrating, and hydrogel-elastomer hybrid material. A bioadhesive may connect the couplant the electronic devices and the person. The couplant may serve as a coupling and transmission for information to or from the electronic device.
Systems and methods for active and passive suppression of the transition from laminar to turbulent fluid flow in conduits for fluid transport, which include pipes, channels, and semi-confined passageways. Examples include implementations of a turbulence model that predicts a turbulence transition mode of a fluid within the conduit and systems and methods for modifying the fluid in the conduit to reduce or suppress the predicted turbulence transition mode and thereby prevent or delay transition of the fluid flow from laminar to turbulent. Examples include active and systems to introduce disturbances into the fluid flow that cancel, absorb, or reduce the predicted turbulence transition mode. Examples include conduit liners configured to absorb energy from the fluid flow at a frequency of the predicted turbulence transition mode. Examples include textures and surface geometries configured to transfer energy in the fluid flow from the predicted turbulence transition mode to a different frequency.
The present disclosure addresses the aforementioned drawbacks by providing systems and methods for securing electronic devices directly on-person in a way that facilitates extended wearing, while properly positioning the electronic device(s) for effective, extended, data gathering. In particular, an elastomer membrane may be utilized and coupled to the electronic device. An electronically-communicable or transmissible material may be arranged within the elastomer membrane. A bioadhesive layer may be coupled to the elastomer membrane on a side opposite to the electronic device and configured to couple the elastomer membrane to the subject.
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
A61B 5/259 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes using conductive adhesive means, e.g. gels
A61B 5/257 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes
NetCast is an optical neural network architecture that circumvents constraints on deep neural network (DNN) inference at the edge. Many DNNs have weight matrices that are too large to run on edge processors, leading to limitations on DNN inference at the edge or bandwidth bottlenecks between the edge and server that hosts the DNN. With NetCast, a weight server stores the DNN weight matrix in local memory, modulates the weights onto different spectral channels of an optical carrier, and distributes the weights to one or more clients via optical links. Each client stores the activations, or layer inputs, for the DNN and computes the matrix-vector product of those activations with the weights from the weight server in the optical domain. This multiplication can be performed coherently by interfering the spectrally multiplexed weights with spectrally multiplexed activations or incoherently by modulating the weight signal from the weight server with the activations.
The present invention provides predictive models for assessing an applicant's risk of defaulting on shared utility service bill payment, such as bill payment for community solar. Described are several alternatives to using FICO score to assess risk. Such alternatives include machine learning techniques (such as random forest classifier) as well as regression analysis.
Systems, articles, and methods directed to electrochemical systems (e.g., batteries) and the electrochemical reduction of halogenated compounds are generally described. In certain embodiments, the halogenated compound comprises at least one sulfur pentahalide (e.g., pentafluoride) group associated with a conjugated system.
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 10/0567 - Liquid materials characterised by the additives
H01M 12/06 - Hybrid cells; Manufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
The present disclosure provides a method of editing a genome in a cell including exposing the cell to an engineered Cas nuclease comprising one or more mutations within the DNA binding cleft of the Cas nuclease, wherein exposure to the engineered Cas nuclease decreases, inhibits, or prevents non-homologous end joining (NHEJ) in the cell, and wherein exposure to the engineered Cas nuclease increases one or more homology-driven repair pathways within the cell. The mutant Cas nuclease is also disclosed herein.
A solar cell can include a first transparent conductive oxide (TCO) layer proximate to a first charge transport layer; a second TCO layer proximate to a second charge transport layer; a perovskite layer disposed between first and second charge transport layers; a first plurality of electrically conductive lines disposed between the first TCO layer and the first charge transport layer; and/or a second plurality of electrically conductive lines disposed between the second TCO layer and second charge transport layer.
62.
GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS
Genome editing tools for use in systems designed to deliver large genetic elements are disclosed herein. A genome editing system is described, which includes i) an R2 element enzyme or other non-LTR site specific retrotransposon element and ii) a payload RNA, wherein the payload RNA comprises an insertion region and optionally one or more of a 5′ homology region, a 3′ homology region, and a protein binding element, wherein the insertion region comprises a template for a small or large nucleic acid insertion into the genome, and wherein the R2 element enzyme or other non-LTR site specific retrotransposon element comprises a targeting domain, a reverse transcriptase domain, and a nickase domain. Also disclosed are cells edited using such a genome editing system, methods for editing a genome, and compositions comprising cells edited with this genomic editing system.
This disclosure provides novel integrases for site-specific genetic engineering. Also provided are systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE) with the novel integrases.
Systems, compositions, and methods for using reactive magnetron sputtering to encapsulate nanowire networks to improve their chemical, thermal, and electrical stability while maintaining transparency are disclosed. For example, oxynitride films are deposited onto silver nanowire networks using full-metal targets without imparting oxidative damage onto the nanowires. The oxynitrides can be deposited using residual water vapor in the chamber that can take advantage of relatively poor vacuum conditions, which would be compatible with high-volume roll-to-roll sputtering approaches, and would also reduce the cost of encapsulating sensitive metal nanostructures which would encounter high temperatures, currents, or humidity. The resulting films can be applicable in a wide variety of fields as transparent encapsulants, where metal nanostructures would need to be protected from harsh environmental conditions and/or high temperatures - including but not limited to: solar cell electrodes, transparent heaters, touch screens, and LEDs.
Aspects of the disclosure relate to non-naturally occurring constructs for the activation of Shank3 gene expression, AAV vectors comprising the constructs, and gene therapy methods
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/00 - Drugs for disorders of the nervous system
66.
PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF
Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.
67.
CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.
An example methodology implementing the disclosed techniques includes receiving a plurality of measured semiconductor properties of one or more partially completed semiconductor devices, determining a measure of short circuit current density (JSC) of each of the one or more partially completed semiconductor devices, the JSC, measure based on a measure of semiconductor diffusion length (LD) and a measure of thickness, and determining a current voltage relationship of each of the one or more partially completed semiconductor devices. The method also includes calculating a current voltage (JV) curve based on the JSC, measure and the current voltage relationship of each of the one or more partially completed semiconductor devices, wherein the JV curve provides an indication of maximum achievable power point (Pmax) and open circuit voltage (Voc) of a semiconductor device completed from the one or more partially completed semiconductor devices, and determining a predicted performance characteristic of the semiconductor device.
A drug delivery device for administration to a subject may include a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device may also include a trigger operatively associated with the potential energy source. The trigger may be configured to actuate at a predetermined location within the subject to deploy a jet of the active pharmaceutical ingredient into a tissue of an adjacent portion of the gastrointestinal tract. In some instances, the jet may be deployed into tissue of the stomach and/or small intestine of the subject. Further, in some embodiments, the operating parameters of the jet may be selected such that the jet penetrates the tissue of the gastrointestinal tract to form a depot of the active pharmaceutical ingredient disposed within the tissue.
Removal of gas-evolving species from powders can be achieved before sintering occurs, reducing or eliminating gas evolution in a dense body that can lead to swelling, or lowering of density.
This disclosure is directed to a targeted delivery vehicle that can deliver a cargo to a cell of interest. The targeted delivery vehicle has a fusogen and a targeting domain which are embedded in a lipid bilayer membrane that forms a vesicle, and a cargo within the vesicle. The disclosure is also directed to methods for targeted delivery of cargo using the targeted delivery vehicle described herein.
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A terahertz imaging system is disclosed. The terahertz imaging system includes a terahertz antenna array, made up of a plurality of antenna elements. Each antenna element includes a patch antenna, a one bit phase shifter, and a plurality of storage elements. The storage elements are used to store a plurality of phase states that are supplied to the one bit phase shifter. The one bit phase shifter is configured to either shift the phase of the incoming signal by 90 or 270, depending on the value of the phase state. The one bit phase shifter is also bidirectional, allowing it to phase shift transmitted signals and reflected signals. A plurality of these antenna elements are disposed in a semiconductor device, where the top metal layer is exposed. This top metal layer is used to create the patch antennas.
H01Q 21/26 - Turnstile or like antennas comprising arrangements of three or more elongated elements disposed radially and symmetrically in a horizontal plane about a common centre
H01Q 3/24 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the orientation by switching energy from one active radiating element to another, e.g. for beam switching
H01Q 3/28 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the amplitude
H01Q 3/30 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase
H01Q 19/10 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces
H01Q 21/22 - Antenna units of the array energised non-uniformly in amplitude or phase, e.g. tapered array or binomial array
Microfluidic chips containing electrochemical biosensors are described. The electrochemical biosensors include a flow layer intersected by valves of a control layer, which control the fluid flow. The flow layer includes two zones, an analyte capture zone for mixing a sample with an analyte capture element, and a detection zone for detecting the analyte. Both zones include a rotary mixer for mixing, and where needed, trapping, washing, and flowing the captured analyte. The captured analyte is detected by the sensing region of the detection zone. The microfluidic chips may be integrated into devices for automated, fast, point-of-care determination of analyte concentration.
An effective amount of one or more microtubule polymerization inhibitors is administered in combination with one or more polo-like kinase (Plk) inhibitors for treating cancer. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree, than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers are also provided.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
The present disclosure provides a method of editing a genome in a cell including exposing the cell to an engineered Cas nuclease comprising one or more mutations within the DNA binding cleft of the Cas nuclease, wherein exposure to the engineered Cas nuclease decreases, inhibits, or prevents non-homologous end joining (NHEJ) in the cell, and wherein exposure to the engineered Cas nuclease increases one or more homology-driven repair pathways within the cell. The mutant Cas nuclease is also disclosed herein.
An ultra-wide bandwidth acoustic transducer may include multiple layers, including an inner piezoelectric layer, a polymer coupling layer and an outer piezoelectric layer. The polymer layer may be located between, and may be bonded to, the inner and outer piezoelectric layers. The transducer may have multiple eigenfrequencies of vibration. These eigenfrequencies may include primary resonant frequencies of the inner and outer piezoelectric layers respectively and may also include resonant frequencies that arise due to coupling between the layers. An acoustic backscatter system may employ such a transducer in backscatter nodes as well as in a transmitter. The multiple eigenfrequencies may enable the system to perform spread-spectrum communication at a high throughput. These multiple eigenfrequencies may also enable each backscatter node to shift frequency of an uplink signal, which in turn may enable the system to mitigate self-interference and to decode concurrent signals from multiple backscatter nodes.
A closed-loop system for blood pressure control that accounts for various mechanisms of the cardiovascular system. In some example cases, a pharmacokinetic-pharmacodynamic model of the cardiovascular system's response to cardiovascular system actuators, such as vasoactive drugs, is generated. Two example actuators are employed in the example framework: phenylephrine, to raise blood pressure, and nicardipine, to lower blood pressure. The pharmacodynamic components employs a two-element Windkessel model. A model predictive control framework is built based on the pharmacokinetic-pharmacodynamic model.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
78.
DIRECTIONAL RECRYSTALLIZATION PROCESSING OF ADDITIVELY MANUFACTURED METAL ALLOYS
A method and apparatus used in preparing a recrystallized metal alloy involve a cooling medium and a heating element to create a cold zone and a hot zone. An additively manufactured metal alloy preform is drawn in a draw direction from the cold zone towards the hot zone to form the recrystallized metal alloy. The cold zone and the hot zone create a surface temperature gradient on at least a portion of the preform of at least about 104K m-1. The step of drawing causes an average grain size of at least a portion of the preform to increase in a direction parallel to the draw direction.
B22F 5/04 - Manufacture of workpieces or articles from metallic powder characterised by the special shape of the product of turbine blades
C22C 19/07 - Alloys based on nickel or cobalt based on cobalt
C22F 1/10 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
79.
CELL-TYPE SPECIFIC TARGETING CONTRACTILE INJECTION SYSTEM
The present disclosure relates generally to the field of delivery systems using contractile injection systems (CIS). Specifically disclosed are engineered extracellular CISs (eCISs) that can deliver non-natural protein payloads to non-natural target cells such as human cells. In addition, methods of using the engineered eCISs are also disclosed.
An effective amount of one or more microtubule polymerization inhibitors is administered in combination with one or more polo-like kinase (Plk) inhibitors for treating cancer. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree, than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers are also provided.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Peptide-E3 ubiquitin ligase fusions representing minimal protein to proteasome linkers are specifically targeted to degrade endogenous FOXP3 proteins in regulatory T cells. An engineered peptide for functional inactivation of a target regulatory T cell includes a fusion protein comprising a targeting domain and a ubiquitin ligase recruiting domain, wherein the targeting domain is engineered to bind FOXP3 of the target regulatory T cell for mediated degradation by the ubiquitin-proteosome pathway. The targeting domain may comprise a peptide having amino acid [SEQ ID No. 3], [SEQ ID No. 4], [SEQ ID No. 5], [SEQ ID No. 6], or [SEQ ID No. 7]. The ubiquitin ligase recruiting domain recruits an E3 ubiquitin ligase, which may be CHIPΔTPR [SEQ ID No. 2]. An engineered minimal, specific, nucleotide-encodable, FOXP3 protein to proteasome linker comprises a peptide-E3 ubiquitin ligase fusion in which the peptide binds to FOXP3. A method for treatment includes administering to a subject an engineered peptide-based therapeutic or pharmaceutically acceptable salt thereof, wherein the engineered peptide-based therapeutic comprises a peptide fusion of a targeting domain and a ubiquitin ligase recruiting domain, and wherein the targeting domain is engineered to bind FOXP3 of at least one regulatory T cell for mediated degradation by the ubiquitin-proteosome pathway.
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 251/08 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
84.
METHOD FOR DESIGN AND MANUFACTURE OF COMPLIANT PROSTHETIC FOOT
A compliant prosthetic foot is designed and fabricated by combining a compliant mechanism optimization technique with a calculation of low leg trajectory error under a reference loading condition. The compliant mechanism optimization technique includes a set of determinants for the compliant prosthetic foot. An optimized set of determinants of the compliant prosthetic foot is formed that minimizes the lower leg trajectory error relative to a target kinematic data set. The compliant prosthetic foot is then fabricated in conformance with the optimized set of determinants.
The introduction of low levels of cleavable comonomer additives into existing vinyl polymerization processes may facilitate the production of chemically deconstructable and recyclable variants with otherwise equivalent properties. The present disclosure describes cleavable comonomer approach as a viable strategy toward circular vinyl polymers. The present disclosure describes copolymers comprising ml instances of the first repeating unit of Formula (i); m2 instances of the second repeating unit of Formula (ii-A) or (ii-B); and optionally one or more types of additional repeating units. The disclosure also provides compounds of the formula:, or a tautomer or salt thereof. The present disclosure further describes methods of preparation, compositions, and kits.
B32B 27/06 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance
B32B 27/24 - Layered products essentially comprising synthetic resin characterised by the use of special additives using solvents or swelling agents
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
B32B 27/04 - Layered products essentially comprising synthetic resin as impregnant, bonding, or embedding substance
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
B32B 27/12 - Layered products essentially comprising synthetic resin next to a fibrous or filamentary layer
The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
King Fahd University of Petroleum & Minerals (Saudi Arabia)
Inventor
Kidambi, Piran
Ibrahim, Ahmed
Laoui, Tahar
Kong, Jing
Karnik, Rohit N
Zhang, Sui
Abstract
Atomically thin layers including pores, their method of manufacture, and their use are disclosed. In some embodiments, pores may be formed in an atomically thin layer by growing the atomically thin layer on exposed portions of a substrate that includes islands comprising a material that is different than the material of the substrate. In some embodiments, pores and/or defects may be formed in an atomically thin layer by employing growth conditions that promote the formation of defects and/or pores. In certain embodiments, pores and/or defects may be etched to enlarge their size.
The invention, in some aspects, includes compositions encoding expression-recording islands (XRIs), compositions comprising XRIs, and methods for using XRIs for intracellular molecular recording.
Methods involving physics-informed deep learning to help solve inverse problems of solid materials/structures related to unknown geometry include (1) identifying and characterizing unknown materials/structures and defects with accuracy and predictive capability and limited non-destructive measurements, and/or (2) designing geometrical features and parameters of solid materials and structures to achieve optimized and/or improved performance.
B29C 64/386 - Data acquisition or data processing for additive manufacturing
B33Y 50/00 - Data acquisition or data processing for additive manufacturing
G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
G01B 21/32 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring the deformation in a solid
B81C 99/00 - Subject matter not provided for in other groups of this subclass
A retrographic sensor includes a flexible transparent structure, a transparent elastomeric pad, and an at least partially reflective layer. The flexible transparent structure may be configured to elastically deform between multiple configurations. At least one light source emits light into the transparent structure. The flexible transparent structure may include one or more markers that are illuminated by the at least one light source. The retrographic sensor may also include a photosensitive detector configured to image the flexible transparent structure and one or more markers. A processor may determine a configuration of the flexible transparent structure based at least in part on an image from the one or more markers.
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes
93.
ORAL APPLIANCE AND METHOD FOR TREATING SLEEP DISORDERS
United States Government as Represented by the Department of Veterans Affairs (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Rasalingam, Ravi
Ward, Tarsha
Venegas, Jose
Roche, Ellen T.
Abstract
An oral appliance and method for treating a sleep disorder in a subject are disclosed. The appliance includes, among other elements, a palatal overlay element that engages a portion of the dorsal surface of the subject's tongue, stabilizing the tongue in a superior direction toward the hard palate. The method generally involves stabilizing the dorsal surface of a subject's tongue in a superior direction toward the subject's hard palate.
A buffered negative electrode-electrolyte assembly includes: a porous negative electrode comprising a metal, a transition metal nitride, or a combination thereof; a solid-state electrolyte; and a buffer layer between the porous negative electrode and the solid-state electrolyte. The buffer layer comprising a buffer composition according to Formula (1) MmNnZzHhXx. The buffer composition has an electronic conductivity that is less than or equal to 1×10-2 times an electronic conductivity of the solid-state electrolyte, and the buffer composition has an ionic conductivity less than or equal to 1×10-6 times an ionic conductivity of the solid-state electrolyte.
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Lang, Jeffrey H.
Yeiser, Aaron J.
Nakajima, Hideko Heidi
Kymissis, Ioannis
Olson, Elizabeth
Mchugh, Christopher I.
Graf, Lukas
Abstract
A piezoelectric sensor and amplifier for use with an auditory aid device are disclosed. The piezoelectric sensor includes a top sensor and a bottom sensor disposed on opposite surfaces of a flex printed circuit board. The top and bottom sensors are made of a piezoelectric material, such as PVDF. Further, the piezoelectric sensor is adapted to be implanted into a subject's ear, where the piezoelectric sensor is cantilevered with the free, or distal end, touching the umbo. The proximal end is held in place by a support that is affixed to the ear. Additionally, the piezoelectric sensor is shaped so that the width of the distal end is less than the width at the proximal end. Further, the piezoelectric sensor generates differential signals, which are then amplified using a differential amplifier circuit.
H02N 2/18 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing electrical output from mechanical input, e.g. generators
H10N 30/30 - Piezoelectric or electrostrictive devices with mechanical input and electrical output, e.g. functioning as generators or sensors
96.
RADIO-FREQUENCY POWER GENERATOR AND CONTROL METHOD
A power generator includes a plurality of amplifier blocks and a combiner. Each of the amplifier blocks include one or more amplifiers, and the combiner combines modulated power signals output from the amplifier blocks to generate an RF power signal of a load. The amplifier blocks are controlled to outphase the modulated power signals based on a phase angle. Ones of the amplifier blocks may perform discrete modulation to generate a respective one of the modulated power signals. The discrete modulation includes selecting different combinations of the amplifiers in one or more of the amplifier blocks to change the RF power signal in discrete steps. In embodiments, the amplifiers may be radio frequency power amplifiers.
TEMASEK LIFE SCIENCES LABORATORY LIMITED (Singapore)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Jang, In-Cheol
Sng, Benny Jian Rong
Singh, Gajendra Pratap
Ram, Rajeev J.
Abstract
The present invention relates to the use of a Raman spectral signature for detection of plant metabolites, specifically carotenoids, in tissue of a plant leaf. Carotenoids are used as a biomarker for an early, real-time diagnosis of shade avoidance syndrome (SAS) in growing plants in a non-invasive or non-destructive way in order to detect the adverse effect of the SAS upon their health, and ultimately their yield. The early, real-time diagnosis of SAS provides a window period within which further adverse effects of SAS may be slowed or prevented without negatively affecting the yield of growing plants or leafy vegetables.
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
A device configured to be implanted in a subject includes a sensing module, a therapeutic module, and a battery. The sensing module includes at least two of an accelerometer, an electrocardiogram (ECG) sensor, a photoplethysmogram (PPG) sensor, and a temperature sensor. The therapeutic module includes a drug reservoir and a reciprocating pump. The battery powers the sensing module and the therapeutic module. The sensing module is configured to detect a biological event in the subject and, upon detection of the biological event, send a signal to the therapeutic module. The therapeutic module is configured to receive the signal from the sensing module and, upon receiving the signal, administer a drug to the subject from the drug reservoir via the pump.
The present disclosure provides compositions and methods for minimally invasive optogenetic stimulation. More particularly, the present disclosure provides compositions and methods for using an ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation.
